165 related articles for article (PubMed ID: 15193251)
21. 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose.
Yamamoto Y; Nishiyama Y; Ishikawa S; Gotoh M; Bandoh S; Kanaji N; Asakura M; Ohkawa M
J Comput Assist Tomogr; 2008; 32(3):432-7. PubMed ID: 18520552
[TBL] [Abstract][Full Text] [Related]
22. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience.
Komori T; Narabayashi I; Matsumura K; Matsuki M; Akagi H; Ogura Y; Aga F; Adachi I
Ann Nucl Med; 2007 Jun; 21(4):209-15. PubMed ID: 17581719
[TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging.
Kobori O; Kirihara Y; Kosaka N; Hara T
Cancer; 1999 Nov; 86(9):1638-48. PubMed ID: 10547535
[TBL] [Abstract][Full Text] [Related]
24. Comparison of MET-PET and FDG-PET for differentiation between benign lesions and malignant tumors of the lung.
Sasaki M; Kuwabara Y; Yoshida T; Nakagawa M; Koga H; Hayashi K; Kaneko K; Chen T; Ichiya Y; Masuda K
Ann Nucl Med; 2001 Oct; 15(5):425-31. PubMed ID: 11758947
[TBL] [Abstract][Full Text] [Related]
25. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.
Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Doi R; Hosotani R; Imamura M; Konishi J
Cancer; 2000 Dec; 89(12):2547-54. PubMed ID: 11135214
[TBL] [Abstract][Full Text] [Related]
26. [
Zheng S; Chen Z; Huang C; Chen Y; Miao W
Ann Nucl Med; 2019 Feb; 33(2):135-143. PubMed ID: 30392070
[TBL] [Abstract][Full Text] [Related]
27. Clinical value of combined positron emission tomography/computed tomography imaging in the interpretation of 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography studies in cancer patients.
Yeung HW; Schöder H; Smith A; Gonen M; Larson SM
Mol Imaging Biol; 2005; 7(3):229-35. PubMed ID: 15912427
[TBL] [Abstract][Full Text] [Related]
28. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
29. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
30. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
31. 18F-FLT PET performs better than 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma.
Yamane T; Takaoka A; Kita M; Imai Y; Senda M
Ann Nucl Med; 2012 Jul; 26(6):478-84. PubMed ID: 22477262
[TBL] [Abstract][Full Text] [Related]
32. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review.
Treglia G; Giovannini E; Di Franco D; Calcagni ML; Rufini V; Picchio M; Giordano A
Ann Nucl Med; 2012 Jul; 26(6):451-61. PubMed ID: 22566040
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic usefulness of an amino acid tracer, α-[N-methyl-(11)C]-methylaminoisobutyric acid ( (11)C-MeAIB), in the PET diagnosis of chest malignancies.
Nishii R; Higashi T; Kagawa S; Kishibe Y; Takahashi M; Yamauchi H; Motoyama H; Kawakami K; Nakaoku T; Nohara J; Okamura M; Watanabe T; Nakatani K; Nagamachi S; Tamura S; Kawai K; Kobayashi M
Ann Nucl Med; 2013 Nov; 27(9):808-21. PubMed ID: 23824782
[TBL] [Abstract][Full Text] [Related]
34. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
35. Dual-phase F-18 FDG PET-CT in staging and lymphoscintigraphy for detection of sentinel lymph nodes in oral cavity cancers.
Sürücü E; Polack BD; Demir Y; Durmuşoğlu M; Ekmekçi S; Sarıoğlu S; Çelik AO; Ada E; İkiz AÖ
Clin Imaging; 2015; 39(5):781-6. PubMed ID: 25721710
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic usefulness of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography in recurrent brain tumor.
Hong IK; Kim JH; Ra YS; Kwon DH; Oh SJ; Kim JS
J Comput Assist Tomogr; 2011; 35(6):679-84. PubMed ID: 22082535
[TBL] [Abstract][Full Text] [Related]
37. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
Dimitrakopoulou-Strauss A; Strauss L
Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
[TBL] [Abstract][Full Text] [Related]
39. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
[TBL] [Abstract][Full Text] [Related]
40. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]